126 related articles for article (PubMed ID: 16189332)
1. [Genetic polymorphism and drug interactions: their importance in the treatment of pain].
Samer CF; Piguet V; Dayer P; Desmeules JA
Can J Anaesth; 2005 Oct; 52(8):806-21. PubMed ID: 16189332
[TBL] [Abstract][Full Text] [Related]
2. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J; Skarke C; Liefhold J; Geisslinger G
Clin Pharmacokinet; 2004; 43(14):983-1013. PubMed ID: 15530129
[TBL] [Abstract][Full Text] [Related]
3. Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.
Solhaug V; Molden E
Scand J Pain; 2017 Oct; 17():193-200. PubMed ID: 29054049
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of analgesics: toward the individualization of prescription.
Rollason V; Samer C; Piguet V; Dayer P; Desmeules J
Pharmacogenomics; 2008 Jul; 9(7):905-33. PubMed ID: 18597654
[TBL] [Abstract][Full Text] [Related]
5. [Interaction of opioid analgesics at the level of biotransformation].
Petri H; Grandt D
Schmerz; 2016 Dec; 30(6):519-525. PubMed ID: 27439327
[TBL] [Abstract][Full Text] [Related]
6. "Weak" opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine.
Prescrire Int; 2016 Feb; 25(168):45-50. PubMed ID: 27042732
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
Haufroid V; Hantson P
Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 in the metabolism of opioids for mild to moderate pain.
Leppert W
Pharmacology; 2011; 87(5-6):274-85. PubMed ID: 21494059
[TBL] [Abstract][Full Text] [Related]
9. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
11. A Single Site Population Study to Investigate CYP2D6 Phenotype of Patients with Persistent Non-Malignant Pain.
Radford H; Simpson KH; Rogerson S; Johnson MI
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31141989
[No Abstract] [Full Text] [Related]
12. Opioid pharmacokinetic drug-drug interactions.
Overholser BR; Foster DR
Am J Manag Care; 2011 Sep; 17 Suppl 11():S276-87. PubMed ID: 21999760
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics in Pain Management.
Saba R; Kaye AD; Urman RD
Anesthesiol Clin; 2017 Jun; 35(2):295-304. PubMed ID: 28526150
[TBL] [Abstract][Full Text] [Related]
14. Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics.
Samer CF; Desmeules JA; Dayer P
Per Med; 2006 Aug; 3(3):239-269. PubMed ID: 29788657
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
16. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
17. The pharmacogenetics of analgesia.
Stamer UM; Stüber F
Expert Opin Pharmacother; 2007 Oct; 8(14):2235-45. PubMed ID: 17927480
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine.
Beulz-Riché D; Grudé P; Puozzo C; Sautel F; Filaquier C; Riché C; Ratanasavanh D
Fundam Clin Pharmacol; 2005 Oct; 19(5):545-53. PubMed ID: 16176333
[TBL] [Abstract][Full Text] [Related]
19. A software tool to adjust codeine dose based on CYP2D6 gene-pair polymorphisms and drug-drug interactions.
Saab Y; Nakad Z
Pharmacogenomics J; 2023 Nov; 23(6):217-224. PubMed ID: 37940650
[TBL] [Abstract][Full Text] [Related]
20. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.
Funck-Brentano C; Boëlle PY; Verstuyft C; Bornert C; Becquemont L; Poirier JM
Eur J Clin Pharmacol; 2005 Dec; 61(11):821-9. PubMed ID: 16315033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
